Cardurion Pharma

Cardurion is a cardiovascular biotechnology company headquartered in Boston, developing new therapies for heart failure and cardiovascular diseases. In July 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced a new preclinical partnership to develop next-generation therapies for the treatment of heart failure and cardiovascular diseases. The partnership with Cardurion follows Takeda's strategy of leveraging external innovation by placing selected assets and outstanding scientists in an entrepreneurial environment, enabling Cardurion's Discovery program.